Inoxgen

Nitric oxide, the active ingredient in Inoxgen, is a vasodilator presented as a medical gas for endotracheopulmonary (inhalation) use. It is employed to manage persistent pulmonary hypertension of the newborn, acute respiratory distress syndrome, and right ventricular failure linked to pulmonary hypertension.

GNH USA supplies Inoxgen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution. Customers benefit from reliable logistics and on‑time delivery.

Inoxgen, a pulmonary vasodilator, is used in conditions characterized by elevated pulmonary vascular resistance. - Persistent pulmonary hypertension of the newborn (PPHN): Improves oxygenation by reducing pulmonary arterial pressure. - Acute respiratory distress syndrome (ARDS): Lowers pulmonary vascular tone to enhance gas exchange. - Right ventricular failure associated with pulmonary hypertension: Decreases right ventricular afterload and supports cardiac output.

Inhaled nitric oxide may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Methemoglobinemia: Elevated methemoglobin levels causing reduced oxygen transport. - Hypotension: Mild systemic blood pressure reduction. - Rebound pulmonary hypertension: Transient increase after discontinuation. - Airway irritation: Cough or throat discomfort. - Nausea: Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe methemoglobinemia: High levels requiring treatment. - Platelet dysfunction: Bleeding tendency. - Nitrogen dioxide formation: Lung irritation if gas purity is compromised. - Hemolysis: In patients with G6PD deficiency. - Acute respiratory distress worsening: Unexpected deterioration.

When using Inoxgen, clinicians should observe specific precautions to ensure safety and efficacy. - Patient selection: Confirm diagnosis of pulmonary hypertension and assess baseline oxygenation. - Monitoring: Continuously monitor methemoglobin levels and pulmonary arterial pressure. - Dose titration: Adjust inhaled concentration gradually to avoid abrupt hemodynamic changes. - Co‑administration: Avoid simultaneous use with other potent vasodilators without supervision. - Contraindications: Do not use in patients with known hypersensitivity to nitric oxide. - Store at ambient temperature: Keep cylinders in a well‑ventilated, dry area away from direct sunlight and heat sources.

Nitric oxide can interact with certain medications and conditions, influencing its safety profile.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors: Combined use may cause excessive pulmonary vasodilation and severe hypotension. - Inhaled anesthetics (e.g., nitrous oxide): May potentiate vasodilatory effects leading to instability.

Moderate Interactions (Monitor Closely): - Anticoagulants: Increased risk of bleeding due to platelet dysfunction. - Hemoglobin‑modifying agents: May exacerbate methemoglobinemia. - Other inhaled gases (e.g., nitric oxide donors): Potential additive toxicity.